Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work | GenomeWeb

This story originally ran on March 30.

German biotech firm Protagen said this week it will use its UNIarray protein array platform to discover biomarkers in support of Biogen Idec's efforts to develop therapies for multiple sclerosis.

The company will use the platform to retrospectively analyze samples from a clinical trial in hopes of finding predictive and response protein biomarkers for relapsing/remitting multiple sclerosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.